 <h1>Ziextenzo Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>pegfilgrastim</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about pegfilgrastim. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ziextenzo.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pegfilgrastim: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pegfilgrastim (the active ingredient contained in Ziextenzo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking pegfilgrastim:</p><p>
<i>More common</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>fever</li>
<li>sore throat</li>
<li>ulcers, sores, or white spots in the mouth</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bluish lips or skin</li>
<li>pain, left upper abdomen or shoulder</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>blisters in the skin</li>
<li>blood in the urine</li>
<li>cloudy urine</li>
<li>decrease in how much or how often you urinate</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fainting or lightheadedness</li>
<li>fast heartbeat</li>
<li>flushing or redness of the skin</li>
<li>hives or welts, skin rash</li>
<li>itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>nausea</li>
<li>sores on the skin</li>
<li>stomach pain</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>unusual tiredness or weakness</li>
<li>unusually warm skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking pegfilgrastim:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Bone pain</li>
<li>chest pain</li>
<li>difficult or labored breathing</li>
<li>eye pain</li>
<li>general feeling of illness</li>
<li>headache </li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pegfilgrastim may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>change in sense of taste</li>
<li>constipation</li>
<li>cracked lips</li>
<li>diarrhea</li>
<li>hair loss or thinning of the hair</li>
<li>heartburn</li>
<li>indigestion</li>
<li>joint pain</li>
<li>lack or loss of strength</li>
<li>loss of appetite</li>
<li>muscle soreness</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble sleeping</li>
<li>vomiting</li>
<li>weakness, generalized</li>
<li>weight loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Body produces substance that can bind to drug making it less effective or cause side effects</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pegfilgrastim: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported side effects included bone pain, skeletal pain, medullary bone pain, and spontaneously reversible mild to moderate lactate dehydrogenase elevations.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Bone pain (up to 31%), skeletal pain (up to 27%), medullary bone pain (up to 26%)</p>
<p><b>Common</b> (1% to 10%): Arthralgia, back pain, extremity pain, limb pain, musculoskeletal pain, myalgia, neck pain, polyarthralgia, polymyalgia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Spontaneously reversible mild to moderate lactate dehydrogenase elevations (up to 18%), spontaneously reversible mild to moderate alkaline phosphatase elevations (up to 11%), spontaneously reversible mild to moderate uric acid elevations (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Spontaneously reversible severe uric acid elevations</p>
<p><b>Frequency not reported</b>: Anorexia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fever, non-cardiac chest pain, pain, pyrexia</p>
<p><b>Frequency not reported</b>: Fatigue, generalized weakness, mucositis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, contact dermatitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute febrile dermatosis, cutaneous vasculitis, erythema/generalized erythema, pruritus, skin rash, Sweet's syndrome, urticaria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukocytosis, thrombocytopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Asymptomatic splenomegaly, fatal splenic rupture, sickle cell crisis, splenic rupture, splenomegaly/enlarged spleen</p>
<p><b>Frequency not reported</b>: Granulocytopenia, neutropenic fever<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Application site reactions, injection site pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Injection site erythema, injection site reactions</p>
<p><b>Postmarketing reports</b>: Application site bruise, application site discomfort, application site hemorrhage, local skin reactions<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1 to 10%): Diarrhea, nausea</p>
<p><b>Frequency not reported</b>: Abdominal pain, constipation, dyspepsia, stomatitis, vomiting<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza, preexisting binding antibodies<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Capillary leak syndrome, flushing, hypotension</p>
<p><b>Rare</b> (0.01% to 0.1%): Aortitis</p>
<p><b>Frequency not reported</b>: Peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Frequency not reported</b>: Dizziness, taste perversion<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Periorbital edema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Acute respiratory distress syndrome (ARDS), dyspnea, fatal ARDS, interstitial pneumonia, pulmonary adverse reactions, pulmonary edema, pulmonary fibrosis, pulmonary infiltrates, respiratory failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis, angioedema, hypersensitivity reactions/hypersensitivity-type reactions, serious allergic reactions</p>
<p><b>Frequency not reported</b>: Allergies to acrylics</p>
<p><b>Postmarketing reports</b>: Allergic reactions, allergic-type reactions, anaphylactic reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Transient elevations in ALT, transient elevations in AST, transient elevations in liver function tests<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Glomerulonephritis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Potential for tumor growth stimulatory effects on malignant cells<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Insomnia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Why do you take Claritin with Neulasta?</li>
<li>When can I remove the Neulasta Onpro?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>When does Neulasta reach peak levels?</li>
<li>Does Neulasta cause bone pain?</li>
<li>How long do the side effects of the Neulasta (pegfilgrastim) shot last?</li>
<li>How do you increase white blood cells during chemo?</li>
<li>Can you shower with Neulasta on body injector?</li>
<li>What does cbqv stand for in pegfilgrastim?</li>
<li>What is the difference between Fulphila and Neulasta?</li>
<li>What is the difference between Udenyca and Neulasta?</li>
<li>What is the difference between Udenyca and Fulphila?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Ziextenzo (pegfilgrastim)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: colony stimulating factors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>ZIEXTENZO Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Neulasta, Udenyca, Fulphila, Nyvepria</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Neutropenia Associated with Chemotherapy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pegfilgrastim: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported side effects included bone pain, skeletal pain, medullary bone pain, and spontaneously reversible mild to moderate lactate dehydrogenase elevations.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Bone pain (up to 31%), skeletal pain (up to 27%), medullary bone pain (up to 26%)</p><p><b>Common</b> (1% to 10%): Arthralgia, back pain, extremity pain, limb pain, musculoskeletal pain, myalgia, neck pain, polyarthralgia, polymyalgia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Spontaneously reversible mild to moderate lactate dehydrogenase elevations (up to 18%), spontaneously reversible mild to moderate alkaline phosphatase elevations (up to 11%), spontaneously reversible mild to moderate uric acid elevations (up to 11%)</p><p><b>Common</b> (1% to 10%): Spontaneously reversible severe uric acid elevations</p><p><b>Frequency not reported</b>: Anorexia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fever, non-cardiac chest pain, pain, pyrexia</p><p><b>Frequency not reported</b>: Fatigue, generalized weakness, mucositis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, contact dermatitis</p><p><b>Uncommon</b> (0.1% to 1%): Acute febrile dermatosis, cutaneous vasculitis, erythema/generalized erythema, pruritus, skin rash, Sweet's syndrome, urticaria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukocytosis, thrombocytopenia</p><p><b>Uncommon</b> (0.1% to 1%): Asymptomatic splenomegaly, fatal splenic rupture, sickle cell crisis, splenic rupture, splenomegaly/enlarged spleen</p><p><b>Frequency not reported</b>: Granulocytopenia, neutropenic fever<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Application site reactions, injection site pain</p><p><b>Uncommon</b> (0.1% to 1%): Injection site erythema, injection site reactions</p><p><b>Postmarketing reports</b>: Application site bruise, application site discomfort, application site hemorrhage, local skin reactions<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1 to 10%): Diarrhea, nausea</p><p><b>Frequency not reported</b>: Abdominal pain, constipation, dyspepsia, stomatitis, vomiting<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza, preexisting binding antibodies<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Capillary leak syndrome, flushing, hypotension</p><p><b>Rare</b> (0.01% to 0.1%): Aortitis</p><p><b>Frequency not reported</b>: Peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Dizziness, taste perversion<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Periorbital edema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Acute respiratory distress syndrome (ARDS), dyspnea, fatal ARDS, interstitial pneumonia, pulmonary adverse reactions, pulmonary edema, pulmonary fibrosis, pulmonary infiltrates, respiratory failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis, angioedema, hypersensitivity reactions/hypersensitivity-type reactions, serious allergic reactions</p><p><b>Frequency not reported</b>: Allergies to acrylics</p><p><b>Postmarketing reports</b>: Allergic reactions, allergic-type reactions, anaphylactic reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Transient elevations in ALT, transient elevations in AST, transient elevations in liver function tests<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Glomerulonephritis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Potential for tumor growth stimulatory effects on malignant cells<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Insomnia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Why do you take Claritin with Neulasta?</li>
<li>When can I remove the Neulasta Onpro?</li>
<li>How many biosimilars have been approved in the United States?</li>
<li>When does Neulasta reach peak levels?</li>
<li>Does Neulasta cause bone pain?</li>
<li>How long do the side effects of the Neulasta (pegfilgrastim) shot last?</li>
<li>How do you increase white blood cells during chemo?</li>
<li>Can you shower with Neulasta on body injector?</li>
<li>What does cbqv stand for in pegfilgrastim?</li>
<li>What is the difference between Fulphila and Neulasta?</li>
<li>What is the difference between Udenyca and Neulasta?</li>
<li>What is the difference between Udenyca and Fulphila?</li>
</ul><h2>More about Ziextenzo (pegfilgrastim)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: colony stimulating factors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>ZIEXTENZO Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Neutropenia Associated with Chemotherapy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>